Fab Pharma S.a.s.

Novartis Ag

Laboratoire Biodim

Mutabilis S.a.

Sonia Escaich

Vincent Gerusz

Mayalen Oxoby

Alexis Denis

Francois Moreau

Yannick Bonvin

Gabor Veres

Heini Ilves

Ernst Boehnlein

François Moreau

The invention relates to novel heterocyclic acrylamide compounds (I), to the preparation of the compounds and intermediates used therein, to the use of the compounds as antibacterial medicaments and pharmaceutical compositions containing the compounds.

Heterocyclic acrylamides and their use as pharmaceuticals

The invention relates to novel heterocyclic acrylamide compounds (I), to the preparation of the compounds and intermediates used therein, to the use of the compounds as antibacterial medicaments and pharmaceutical compositions containing the compounds. 

The invention relates to novel acylpiperazinone compounds, to the preparation of the compounds and intermediates used therein, to the use of the compounds as antibacterial medicaments and pharmaceutical compositions containing the compounds.

Acylpiperazinones and their use as pharmaceuticals

The invention relates to Imidazolo-heteroaryl derivatives of formula (I). The compounds inhibit the activity of the Dlta enzyme of Gram-positive bacteria and are useful to treat Gram-positive bacterial infections. Furthermore the application discloses method for assessing the Dlta inhibitory activity of tested molecules and a method for measuring the efficacy of molecules in inhibiting bacteria proliferation in vitro. 

Imidazolo-heteroaryl derivatives with antibacterial properties

Novel antisense sequences to the unspliced or single spliced portions of mRNA transcript from HIV-1 provirus, optionally co-expressed with an inhibitory transdominant mutant HIV-1 protein, are found to be useful in the treatment of HIV-1 infection.

Growing community of inventors

Paris, France

Sonia Escaich